Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBaylor Scott & White Step Therapy Update | OpenPay…
    Ask Trek AI about this page
    CurrentBaylor Scott & White Health PlanPolicy 306

    Step Therapy Policy - Commercial plans

    Customize your policy alerts

    Sign up for Baylor Scott & White Health Plan Policy 306 alerts

    Get alerted when Policy 306 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs step therapy requirements for commercial-plan medical outpatient drugs and devices, requiring a trial of applicable preferred alternatives before coverage of non-preferred products. It applies to providers requesting coverage for members and must be used with the member’s benefit document and referenced Baylor Scott & White Health Plan policies.

    Policy Summary
    PayerBaylor Scott & White Health Plan
    PolicyStep Therapy Policy - Commercial plans
    Policy CodePolicy 306
    Change TypePolicy update
    Effective DateOct 1, 2026
    Last ReviewSep 24, 2026
    Next Review DateSep 24, 2027
    Key ActionSubmit documentation of adequate trials, clinically significant intolerance, or contraindication to every applicable preferred drug that can be used for the requested indication.
    SourceLink
    POLICY UPDATE CHANGES

    Vykoura was added to the leucovorin class.

    The policy history documents additions and updates to several drug classes, including infliximab agents and specialty oncology and ophthalmic products.

    A reference to policy 239 was removed.

    ALLPreferred alternatives required
    2Medical-necessity requirements
    14Drug or therapeutic classes

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    AvailableTexas exceptions
    ParityUnlisted outpatient drugs

    Coverage Criteria

    Non-preferred drug coverage

    A non-preferred medication is medically necessary when all of the following are met.

    Non-preferred drug medical necessity

    • Preferred-drug requirement: The member has failed an adequate trial of, or has clinically significant intolerance or contraindication to, every preferred drug in the same class that can also be used for the requested indication.All applicable preferred drugs

      Failure of an adequate trial of preferred-product biosimilars alone does not satisfy medical necessity.

    • Additional Plan criteria: The member meets the additional clinical coverage criteria in the applicable Baylor Scott & White Health Plan policy.Per applicable Plan policy

    Texas step-therapy exceptions

    For plans subject to applicable Texas Department of Insurance requirements, step therapy is not required when an exception applies.

    Texas regulatory exceptions

    • Advanced metastatic cancer exception: Use of the requested non-preferred drug is consistent with best practices for the treatment of stage-four advanced or metastatic cancer or an associated condition, is supported by peer-reviewed, evidence-based literature, and is approved by the United States Food and Drug Administration.All three elements

      Per Texas Mandate HB1584 and Texas Insurance Code section 1369.213.

    • Contraindication, ineffectiveness, or harm exception: Use of the requested non-preferred drug is contraindicated, expected to be ineffective, or expected to cause harm based on submitted clinical documentation and/or medical literature.At least one supported circumstance

      Per Texas Insurance Code section 1369.0546.

    Failure of an adequate trial of preferred-product biosimilars alone does not qualify the member for coverage of the non-preferred drug. The request must otherwise satisfy the applicable coverage requirements.

    A request for a non-preferred drug does not establish medical necessity when it is based only on failure of an adequate trial of biosimilars of preferred products. Medical necessity requires failure, clinically significant intolerance, or contraindication to all applicable preferred drugs, along with the additional criteria in the applicable Plan policy.

    Coding and Product Coverage

    Non-preferred bevacizumab oncology productHCPCSNot Covered
    J9035Avastin

    Provider Actions and Documentation

    Note

    Review the Applicable Drug or Device Policy

    Before applying the supplemental step-therapy requirements, review the applicable Baylor Scott & White Health Plan medical policy governing the requested drug or device. Direct providers to the specific drug or device policy for the applicable prior-authorization and coverage criteria.

    Step Therapy

    Preferred-Product Trial Required

    For a non-preferred drug or device, document an adequate trial of the preferred therapeutic alternative(s) required for the requested indication before requesting coverage.

    • The member must have failed an adequate trial of all preferred drugs in the same class that can also be used for the requested indication.
    Documentation Required

    Step-Therapy Background

    Step therapy is a utilization-management approach that requires a preferred therapeutic alternative to be tried before coverage of a non-preferred drug or device for a specific indication. For non-preferred drug requests, the applicable Baylor Scott & White Health Plan medical policy is applied first, followed by the supplemental requirements in this policy.

    Key Definitions

    Step therapy
    DefinitionA requirement to try a preferred therapeutic alternative before coverage of a non-preferred drug or device for a specific indication.
    SequenceThe applicable Baylor Scott & White Health Plan medical policy is applied first, followed by the supplemental step-therapy requirements.
    Coverage targetThe requirement applies before coverage of a non-preferred drug or device.
    Adequate trial
    DefinitionA trial sufficient to establish failure of the preferred drug for the requested indication.
    Qualifying failureThe member must have failed an adequate trial of all preferred drugs in the same class that can also be used for the requested indication.

    Initial Non-Preferred Drug Requests

    Initial non-preferred drug request

    For initial coverage of a non-preferred drug, apply all of the following requirements.

    Initial non-preferred therapy

    • The member has failed an adequate trial of, or has clinically significant intolerance or contraindication to, every preferred drug in the same class that can be used for the requested indication.All applicable preferred drugs

      Failure of an adequate trial of preferred-product biosimilars alone is insufficient.

    • The member meets the additional clinical coverage criteria in the applicable Baylor Scott & White Health Plan policy.Per applicable Plan policy

    Preferred and Non-Preferred Product Pathways

    Drug or classPreferred product(s) to try firstNon-preferred product(s)Policy or limitation
    BendamustineBelrapzo; BendekaBendamustine 505b2 formulations; VivimustaApply the applicable cancer policy.
    Drug or classPreferred product(s) to try firstNon-preferred product(s)Policy or limitation
    Bevacizumab for oncology indicationsMvasi; ZirabevAvastin; Alymsys; Avzivi; VegzelmaOncology indications only.
    Drug or classPreferred product(s) to try firstNon-preferred product(s)Policy or limitation
    Bone antiresorptive therapy for oncology indicationsZoledronic acidOther listed oncology bone antiresorptive products, including Aukelso, Bomyntra, Bilprevda, Osenvelt, Wyost, Xbryk, Xgeva, Xtrenbo, and other denosumabDoes not apply to prostate or breast cancer; apply the applicable cancer policy.
    Drug or classPreferred product(s) to try firstNon-preferred product(s)Policy or limitation
    Botulinum toxinsBotox; DysportMyobloc; Xeomin; Daxxify; other botulinum toxin agentsApply the applicable medical-insurance policy.
    Drug or classPreferred product(s) to try firstNon-preferred product(s)Policy or limitation
    Immune globulins and sickle-cell gene therapiesApply the preferred products and criteria in the applicable Plan policiesApplicable non-preferred productsRefer to Policy 045, Immune Globulin Therapy; Policy 310, Exagamglogene autotemcel; and Policy 311, Lovotibeglogene autotemcel (Lyfgenia), as applicable.
    Drug or classPreferred product(s) to try firstNon-preferred product(s)Policy or limitation
    InfliximabUnbranded infliximab; RemicadeAvsola; Inflectra; RenflexisApply the applicable medical-insurance policy.
    Drug or classPreferred product(s) to try firstNon-preferred product(s)Policy or limitation
    IrinotecanConventional irinotecan, generic or brandIrinotecan liposomalApply the applicable cancer policy.
    Drug or classPreferred product(s) to try firstNon-preferred product(s)Policy or limitation
    LeucovorinFusilevKhapzory; current leucovorin class listing, including VykouraUse the current class listing and apply the applicable cancer policy.
    Drug or classPreferred product(s) to try firstNon-preferred product(s)Policy or limitation
    Long-acting G-CSFUdenycaFulphila; Fylnetra; NyvepriaApply the applicable cancer or medical-insurance policy.
    Drug or classPreferred product(s) to try firstNon-preferred product(s)Policy or limitation
    PD-1 inhibitors for metastatic nasopharyngeal cancerLoqtorziKeytruda; OpdivoMetastatic nasopharyngeal cancer only; apply the applicable cancer policy.
    Drug or classPreferred product(s) to try firstNon-preferred product(s)Policy or limitation
    PemetrexedPemetrexed, generic or brand, including AlimtaAxtle; Pemfexy; Pemrydi RTU; other pemetrexed 505b2 productsApply the applicable cancer policy.
    Drug or classPreferred product(s) to try firstNon-preferred product(s)Policy or limitation
    RituximabRuxienceRiabni; Rituxan; Rituxan Hycela; other rituximab-containing agentsApply the applicable medical-insurance or cancer policy.
    Drug or classPreferred product(s) to try firstNon-preferred product(s)Policy or limitation
    Short-acting G-CSFZarxioGranix; Neupogen; Nivestym; Releuko; other short-acting G-CSF productsApply the applicable medical-insurance or cancer policy.
    Drug or classPreferred product(s) to try firstNon-preferred product(s)Policy or limitation
    TaxanesPaclitaxel, including TaxolDocetaxel 505b2 formulations; paclitaxel protein-bound, including AbraxaneDoes not apply to pancreatic cancer; apply the applicable cancer policy.
    Drug or classPreferred product(s) to try firstNon-preferred product(s)Policy or limitation
    TrastuzumabKanjinti; OntruzantHerceptin; Herceptin Hylecta; Herzuma; Ogivri; Trazimera; other trastuzumab productsIncludes listed 505b2 formulations; apply the applicable cancer policy.
    Drug or classPreferred product(s) to try firstNon-preferred product(s)Policy or limitation
    Trop-2-directed antibody and topoisomerase inhibitorTrodelvyDatrowayApply the applicable cancer policy.
    Drug or classPreferred product(s) to try firstNon-preferred product(s)Policy or limitation
    Intravenous ustekinumabSelarsdi; SteqeymaImuldosa; Otulfi; Pyzchiva; Stelara; Wezlana; unbranded ustekinumab; other ustekinumab biosimilarsApply the applicable medical-insurance policy.
    Drug or classPreferred product(s) to try firstNon-preferred product(s)Policy or limitation
    Ophthalmic agentsPreferred ophthalmic product(s) listed in the applicable policyBeovu; Byooviz; Eylea; Eylea HD; Lucentis; Pavblu; Susvimo; VabysmoOphthalmic indications only; apply Policy 215, Medications Covered Under Medical Insurance Policy.

    Preferred Biosimilar Products

    Billing Rule

    Preferred bendamustine products

    Use Belrapzo or Bendeka as the preferred bendamustine products before requesting non-preferred bendamustine 505b2 formulations or Vivimusta, subject to the applicable cancer policy.

    • Preferred: Belrapzo
    • Preferred: Bendeka
    Billing Rule

    Preferred oncology bevacizumab products

    For oncology indications, use Mvasi or Zirabev as the preferred bevacizumab products before requesting a non-preferred product.

    • Preferred: Mvasi; Zirabev
    • Non-preferred: Avastin, Alymsys, Avzivi, and Vegzelma
    • HCPCS J9035 identifies Avastin.
    Policy Summary
    PayerBaylor Scott & White Health Plan
    PolicyStep Therapy Policy - Commercial plans
    Policy CodePolicy 306
    Change TypePolicy update
    Effective DateOct 1, 2026
    Last ReviewSep 24, 2026
    Next Review DateSep 24, 2027
    Key ActionSubmit documentation of adequate trials, clinically significant intolerance, or contraindication to every applicable preferred drug that can be used for the requested indication.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Product CoverageProvider Actions and DocumentationStep-Therapy BackgroundKey DefinitionsInitial Non-Preferred Drug RequestsPreferred and Non-Preferred Product PathwaysPreferred Biosimilar Products

    Document Preferred-Drug Trial History

    Submit documentation of the member’s trial history for each applicable preferred drug, including treatment failure, clinically significant intolerance, or a contraindication. The record should identify the drug, indication, trial duration or relevant exposure, outcome, and the clinical basis for intolerance or contraindication.

    • Document failure of an adequate trial, clinically significant intolerance, or contraindication for all applicable preferred drugs.
    Documentation Required

    Support Applicable Texas Exceptions

    For plans subject to Texas Department of Insurance requirements, submit clinical documentation and, when applicable, medical literature supporting an exception to step therapy. The documentation must establish the applicable statutory exception rather than merely state that the preferred product was not selected.

    • Support contraindication, expected ineffectiveness, or expected harm with submitted clinical documentation and/or medical literature under TIC §1369.0546.
    • For the advanced-cancer exception, also document consistency with best practices and FDA approval.
    Documentation Required

    Advanced Metastatic Cancer Exception

    Step therapy is not required for a non-preferred drug used consistently with best practices for stage-four advanced, metastatic cancer or an associated condition when the use is supported by peer-reviewed, evidence-based literature and approved by the U.S. Food and Drug Administration.

    • Document the stage-four advanced or metastatic cancer diagnosis, or associated condition.
    • Provide peer-reviewed, evidence-based literature supporting the requested use.
    • Document the applicable U.S. Food and Drug Administration approval.
    Denial Risk

    Failure to Try All Preferred Drugs

    A request for a non-preferred drug may not meet medical necessity when the member has not failed an adequate trial of every preferred drug in the same class that can also be used for the requested indication.

    • Do not rely on failure of only one preferred drug when other applicable preferred drugs remain untried.
    • Document a contraindication or clinically significant intolerance when a preferred drug cannot reasonably be tried.
    Denial Risk

    Biosimilar-Only Failure Is Insufficient

    Failure of a biosimilar of a preferred product alone does not establish medical necessity for the requested non-preferred drug. A request based on biosimilar-only failure may be denied under this policy.

    • An adequate trial of biosimilars of preferred products does not satisfy the preferred-drug step-therapy requirement.
    Denial Risk

    Meet Referenced Plan Policy Criteria

    After the applicable Baylor Scott & White Health Plan medical policy is applied, the member must meet any additional clinical coverage criteria specified in that Plan policy. Include the clinical information required by the referenced policy with the request.

    • Requests that do not meet the referenced Plan policy’s additional clinical criteria may be denied, even when step-therapy documentation is submitted.
    Other qualifying circumstancesClinically significant intolerance or contraindication to an applicable preferred drug may also support coverage of the non-preferred drug.
    Required scopeThe trial, intolerance, or contraindication must apply to all preferred drugs that can be used for the requested indication.
    Billing Rule

    Preferred trastuzumab products

    Use Kanjinti or Ontruzant as the preferred trastuzumab products before requesting other listed trastuzumab products.

    • Preferred: Kanjinti
    • Preferred: Ontruzant
    Billing Rule

    Preferred rituximab product

    Use Ruxience as the preferred rituximab product before requesting Riabni, Rituxan, Rituxan Hycela, or other rituximab-containing agents.

    • Preferred: Ruxience
    Billing Rule

    Preferred intravenous ustekinumab products

    For intravenous ustekinumab, use Selarsdi or Steqeyma as the preferred products before requesting Imuldosa, Otulfi, Pyzchiva, Stelara, Wezlana, unbranded ustekinumab, or other ustekinumab biosimilars.

    • Preferred: Selarsdi; Steqeyma
    • Non-preferred: Imuldosa, Otulfi, Pyzchiva, Stelara, Wezlana, unbranded ustekinumab, and other ustekinumab biosimilars